Related Experiment Video

Updated: Jun 2, 2026

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Sensitizing Lung Cancer to Immunotherapy with a RAS(ON) Inhibitor Doublet

Miriam Molina-Arcas1, Julian Downward1

  • 1Francis Crick Institute , London, United Kingdom.

Cancer Discovery
|June 1, 2026
PubMed

Insights

A new combination of RAS inhibitors, targeting both specific and all RAS forms, significantly reduces drug resistance. This doublet therapy, combined with immune checkpoint blockade, offers hope for treating refractory RAS-mutant cancers.

Area of Science:

  • Oncology
  • Immunology
  • Drug Development

Background:

  • First-generation RAS inhibitors have shown limited clinical success.
  • RAS mutations are common drivers in many refractory cancers.
  • Drug resistance remains a significant challenge in cancer therapy.

Purpose of the Study:

  • To evaluate a novel combination of ON-state RAS inhibitors.
  • To assess the efficacy of this RAS inhibitor doublet in combination with immune checkpoint blockade.
  • To explore a new therapeutic strategy for RAS-mutant cancers.

Main Methods:

  • Preclinical study design.
  • Utilized a combination of a mutant-selective and a pan-RAS inhibitor.
  • Investigated combination therapy with immune checkpoint blockade.

Main Results:

  • The RAS inhibitor doublet demonstrated reduced development of drug resistance.
  • Combination therapy with immune checkpoint blockade achieved complete immune elimination of refractory cancers.
  • Effective in 'immune-cold' tumor microenvironments.

Conclusions:

  • Combination RAS inhibition can overcome drug resistance.
  • RAS inhibitor doublet combined with immunotherapy shows potent anti-cancer activity.
  • This strategy holds promise for treating challenging RAS-mutant tumors.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...